Brief: Moleculin Receives Positive FDA Guidance For Its Trial For R/R Acute Myeloid Leukemia

Moleculin Biotech

13/02/2025 14:29

Feb 13 (Reuters) - Moleculin Biotech Inc  MBRX.O :
    * MOLECULIN RECEIVES POSITIVE FDA GUIDANCE FOR ACCELERATION
OF ITS
REGISTRATION-ENABLING MIRACLE TRIAL FOR R/R ACUTE MYELOID
LEUKEMIA (AML)
    * MOLECULIN BIOTECH INC - FDA ALLOWS REDUCTION IN SIZE OF
MOLECULIN'S PHASE 3 TRIAL
    * MOLECULIN BIOTECH INC - AMENDED PROTOCOL ALLOWS UNBLINDING
OF
DATA AT 45 SUBJECTS
    * MOLECULIN BIOTECH INC - FIRST UNBLINDING EXPECTED IN
SECOND HALF
OF 2025

Source text:  ID:nPn1DNcZga 
Further company coverage:  MBRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))